The effect of trastuzumab on cardiac function in patients with HER2‐positive metastatic breast cancer and reduced baseline left ventricular ejection fraction

The effect of trastuzumab on cardiac function in patients with HER2‐positive metastatic breast cancer and reduced baseline left ventricular ejection fraction

We investigated the effect of trastuzumab on cardiac function in a real‐world historic cohort of patients with HER2‐positive metastatic breast cancer (MBC) with reduced baseline left ventricular ejection fraction (LVEF). Thirty‐seven patients with HER2‐positive MBC and baseline LVEF of 40% to 49% we...

Ausführliche Beschreibung

Gespeichert in:
Bibliographische Detailangaben
Veröffentlicht in:International journal of cancer 2022-08, Vol.151 (4), p.616-622
Hauptverfasser: Bouwer, Nathalie I., Steenbruggen, Tessa G., Rier, Hánah N., Kitzen, Jos J. E. M., Smorenburg, Carolien H., Bekkum, Marlies L., Jong, Paul C., Drooger, Jan C., Holterhues, Cynthia, Kofflard, Marcel J. M., Boersma, Eric, Sonke, Gabe S., Levin, Mark‐David, Jager, Agnes
Format: Artikel
Sprache:eng
Schlagworte:
Breast cancer
Cancer
Cancer Therapy and Prevention
Cardiac function
Cardiotoxicity
Ejection fraction
ErbB-2 protein
Heart
HER2‐positive metastatic breast cancer
impaired baseline LVEF
Medical research
Metastases
Metastasis
Monoclonal antibodies
Targeted cancer therapy
Trastuzumab
Ventricle
Online-Zugang:Volltext
Tags: Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
Beschreibung
Zusammenfassung:We investigated the effect of trastuzumab on cardiac function in a real‐world historic cohort of patients with HER2‐positive metastatic breast cancer (MBC) with reduced baseline left ventricular ejection fraction (LVEF). Thirty‐seven patients with HER2‐positive MBC and baseline LVEF of 40% to 49% were included. Median LVEF was 46% (interquartile range [IQR] 44%‐48%) and median follow‐up was 18 months (IQR 9‐34 months). During this period, the LVEF did not worsen in 24/37 (65%) patients, while 13/37 (35%) patients developed severe cardiotoxicity defined as LVEF
ISSN:0020-7136
1097-0215
DOI:10.1002/ijc.34024